Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.

Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, Radic HD, Chamberlain CA, Hölmich LR, Hendel HW, Larsen MS, Met Ö, Svane IM, Donia M.

Ann Oncol. 2018 Jul 1;29(7):1575-1581. doi: 10.1093/annonc/mdy139.

PMID:
29688262
2.

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met Ö, Hansen M, Lindberg H, Sengeløv L, Svane IM.

Cytotherapy. 2017 Apr;19(4):500-513. doi: 10.1016/j.jcyt.2017.01.007. Epub 2017 Feb 15.

PMID:
28215654
3.

Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.

Kongsted P, Svane IM, Lindberg H, Sengeløv L.

Clin Genitourin Cancer. 2017 Apr;15(2):e281-e287. doi: 10.1016/j.clgc.2016.08.019. Epub 2016 Sep 8.

PMID:
27692811
4.

Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer.

Kongsted P, Svane IM, Lindberg H, Bisbjerg R, Daugaard G, Sengeløv L.

Anticancer Drugs. 2016 Aug;27(7):695-701. doi: 10.1097/CAD.0000000000000375.

PMID:
27148775
5.

Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer.

Kongsted P, Svane IM, Lindberg H, Sengeløv L.

Clin Genitourin Cancer. 2016 Dec;14(6):e559-e568. doi: 10.1016/j.clgc.2016.03.018. Epub 2016 Mar 24.

PMID:
27102406
6.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH, Thor Straten P, Svane IM.

Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22.

7.

Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?

Kongsted P, Svane IM, Lindberg H, Daugaard G, Sengeløv L.

Urol Oncol. 2015 Nov;33(11):494.e15-20. doi: 10.1016/j.urolonc.2015.06.022. Epub 2015 Aug 5.

PMID:
26254696
8.

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.

Hjortsø MD, Larsen SK, Kongsted P, Met Ö, Frøsig TM, Andersen GH, Ahmad SM, Svane IM, Becker JC, Straten PT, Andersen MH.

Oncoimmunology. 2015 Jan 30;4(1):e968480. eCollection 2015 Jan.

9.

[Fatal neutropenic enterocolitis in a patient with castration-resistant prostate cancer treated with first-line chemotherapy].

Kongsted P, Sheikh K, Mouritsen LS, Lindberg H, Sengeløv L.

Ugeskr Laeger. 2015 Jan 26;177(2A):24-5. Danish.

PMID:
25612951
10.

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.

Idorn M, Køllgaard T, Kongsted P, Sengeløv L, Thor Straten P.

Cancer Immunol Immunother. 2014 Nov;63(11):1177-87. doi: 10.1007/s00262-014-1591-2. Epub 2014 Aug 2.

PMID:
25085000

Supplemental Content

Loading ...
Support Center